New NHS operational planning guidance – what does it mean for pharma?
Why is the new NHS operational planning guidance so significant and what does it mean for pharmaceutical companies? Oli Hudson, Content Director at Wilmington...
Pf Awards 2021 – responding to the pandemic
The introduction of a new Pf Awards category for 2021 - Responsive Company Strategy - gave insight into companies who specifically demonstrated a rapid,...
What does it really take to conduct a vaccine trial at scale?
The Pfizer/BioNTech COVID-19 vaccine trial was one of the largest and fastest clinical trials ever conducted. ICON, a global provider of outsourced drug and...
COVID-19 and the impact on heart failure care
As the coronavirus pandemic continues to strain healthcare services in the UK, findings from the first patient survey into the impact of COVID-19 on...
Talking heads – what can pharma learn from 2020?
As we enter a new year and a next normal, taking time to reflect on the challenges and opportunities that 2020 presented to pharma...
The future of clinical research
Clinical research is the most expensive and often most time-consuming phase of drug development. This fact puts huge commercial pressures on businesses and, in...
Bringing in change with Brexit
With a post-Brexit deal agreed, it is time to weigh up the opportunities and the risks for industry. From clinical trials to marketing authorisation,...
The cost of COVID-19 on lung cancer progress
Lung cancer is the largest cause of cancer deaths in the world and there is no doubt that the COVID-19 pandemic has had a...
How the NHS and pharma are working together to improve cancer services
Despite a difficult year for cancer services, cancer survival rates are improving in the UK, and it is vital that all parts of the...
The importance of adherence
What makes the difference between a patient with a chronic condition adhering or not adhering to treatment? Poor adherence to treatment of chronic disease has...
Latest articles
NICE recommends Tagrisso for patients with early-stage lung cancer
Following a positive final recommendation from the National Institute for Health and Care Excellence (NICE), AstraZeneca’s Tagrisso (osimertinib) is now available as an adjuvant...
JCVI responds to Omicron variant and updates its guidance
The Joint Committee on Vaccination and Immunisation (JCVI) has responded to the emergence of the Omicron variant and updated its guidance, with immediate effect. A...
EC grants marketing authorisation for breast cancer treatment Trodelvy
The European Commission (EC) has granted marketing authorization for Gilead Sciences’ Trodelvy® (sacituzumab govitecan), as a monotherapy indicated for the treatment of adult patients with...
Popular articles
New Normal, New Thinking: Life Post COVID-19
New thinking will be required to adapt to the new normal life post COVID-19. I hate to start this article on a negative note, but...
NICE recommends Tagrisso for patients with early-stage lung cancer
Following a positive final recommendation from the National Institute for Health and Care Excellence (NICE), AstraZeneca’s Tagrisso (osimertinib) is now available as an adjuvant...
A CLASS DIVIDED – A LIFE CHANGING EXPERIMENT
What can your team learn about positive thinking from a schoolteacher in the 1970s and a world heavy weight champion? Ama Verdi-Ashton explains. It...
JCVI responds to Omicron variant and updates its guidance
The Joint Committee on Vaccination and Immunisation (JCVI) has responded to the emergence of the Omicron variant and updated its guidance, with immediate effect. A...
Understanding the role of the MSL
Helen Kane surveyed more than 200 medical science liaisons (MSLs) to understand more about their current in-role reality. She gave Pf Magazine exclusive access...